Phase 1 HER2-negative Breast Cancer Clinical Trials
13 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–13 of 13 trials
Recruiting
Phase 1Phase 2
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Metastatic Breast CancerHR+/HER2-negative Breast Cancer
SynDevRx, Inc.52 enrolled10 locationsNCT05455619
Recruiting
Phase 1
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
HR+/HER2-negative Breast Cancer
Totus Medicines241 enrolled18 locationsNCT05683418
Recruiting
Phase 1Phase 2
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Breast CancerMetastatic Breast CancerBreast Cancer Female+2 more
Sarah Sammons, MD65 enrolled1 locationNCT07198724
Recruiting
Phase 1Phase 2
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Metastatic Breast CancerHER2-negative Breast CancerAdvanced Breast Cancer+1 more
RayzeBio, Inc.124 enrolled31 locationsNCT06590857
Recruiting
Phase 1
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Breast CancerBreast Cancer MetastaticMetastatic Breast Cancer+3 more
Memorial Sloan Kettering Cancer Center28 enrolled7 locationsNCT06678269
Recruiting
Phase 1
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Breast Cancer MetastaticPancreatic CancerHER2-negative Breast Cancer+9 more
General Oncology, Inc.24 enrolled2 locationsNCT04150042
Recruiting
Phase 1
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
HER2-negative Breast CancerBreast Cancer Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute18 enrolled1 locationNCT06691035
Recruiting
Phase 1
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Breast CancerMetastatic Breast CancerHER2-negative Breast Cancer+4 more
Relay Therapeutics, Inc.930 enrolled37 locationsNCT05216432
Recruiting
Phase 1Phase 2
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer
Inoperable Locally Advanced HER2-Negative Breast CancerMetastatic HER2-Negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd180 enrolled1 locationNCT06942234
Recruiting
Phase 1
Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
Breast CancerHER2-negative Breast CancerBRCA1 Mutation+2 more
Dana-Farber Cancer Institute20 enrolled3 locationsNCT06488378
Recruiting
Phase 1
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Metastatic Breast CancerHER2-negative Breast Cancer
University of Texas Southwestern Medical Center30 enrolled7 locationsNCT05029999
Recruiting
Phase 1
PRE-I-SPY Phase I/Ib Oncology Platform Program
Metastatic Breast CancerHER2-negative Breast CancerMetastatic Cancer+5 more
QuantumLeap Healthcare Collaborative124 enrolled7 locationsNCT05868226
Recruiting
Phase 1
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
Breast CancerHER2-negative Breast CancerHyperinsulinism
Yale University20 enrolled1 locationNCT05989347